peter attia tirzepatide New insights on GLP-1 agonists—Ozempic, Wegovy, Mounjaro, and more (AMA 64 sneak peek) Influence of Type 2 Diabetes

[DOI] [PubMed] [Google Scholar] 154.Hare K.J., Knop F.K., Asmar M., Madsbad S., Deacon C.F., Holst J.J., et al

Lyophilized peptides stored at -20 degrees Celsius can maintain their potency for years

Nslund E, Gutniak M, Skogar S, et al

Active-duty members must be particularly cautious to ensure their treatment is documented and approved to avoid administrative pitfalls

Retatrutide is not uniquely problematic for muscle loss

Mounjaro is a dual GIP and GLP-1 receptor agonist licensed in the UK for chronic weight management in adults with obesity or overweight with weight-related comorbidities, as well as for type 2 diabetes